The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function

PLoS ONE - United States
doi 10.1371/journal.pone.0039163
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Mechanism of Inhibition for BMS-791325, a Novel Non-Nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2014English

Binding Site Characterization and Resistance to a Class of Non-Nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2005English

In Silico Screening for Human Norovirus Antivirals Reveals a Novel Non-Nucleoside Inhibitor of the Viral Polymerase

Scientific Reports
Multidisciplinary
2018English

Molecular Modeling Study on the Drug Resistance Mechanism of NS5B Polymerase to TMC647055

Biochemistry and Cell Biology
BiochemistryCell BiologyMolecular Biology
2016English

Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase

Cell
BiochemistryGeneticsMolecular Biology
2017English

Molecular Mechanism Underlying the Action of a Novel Fusion Inhibitor of Influenza a Virus.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1997English

Dynamics of Hepatitis C Virus (HCV) RNA-dependent RNA Polymerase NS5B in Complex With RNA

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2014English

Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2012English

Erratum To: Ebselen Is a Potent Non-Competitive Inhibitor of Extracellular Nucleoside Diphosphokinase

Purinergic Signalling
Molecular NeuroscienceCell BiologyMolecular BiologyCellular
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy